PK MED
Created in 2019
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
622Activities
Technologies
Entity types
Location
14 Rue Jean Antoine de Baïf, 75013 Paris, France
Paris
France
Employees
Scale: 2-10
Estimated: 10
Engaged corporates
5
1 4Added in Motherbase
1 month, 4 weeks ago
deeptech Value proposition
Tailor-designed drug implants for local treatments.
Founded by Truffle Capital.
PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a European Venture Capital firm specializing in Life sciences. PK MED was created around a small team of passionate and experienced experts in pharmaceutical and medical sciences, drug delivery and biomaterials design.
PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Our expertise spans across critical healthcare domains, focusing on drug delivery systems for rheumatology and enhancing cell-homing techniques to improve bone marrow transplantation outcomes.
The company has developed a portfolio of early projects in indications with high unmet medical needs, starting with Gout flare, Osteoarthritis and Hemoglobinopathies.
Drug Delivery, Drug reformulation, Drug repurposing, Biomaterials, Pharmaceuticals, Biotechnology, BioTech, and InnovationOriginal language
Tailor-designed drug implants for local treatments.
Founded by Truffle Capital.
PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a European Venture Capital firm specializing in Life sciences. PK MED was created around a small team of passionate and experienced experts in pharmaceutical and medical sciences, drug delivery and biomaterials design.
PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Our expertise spans across critical healthcare domains, focusing on drug delivery systems for rheumatology and enhancing cell-homing techniques to improve bone marrow transplantation outcomes.
The company has developed a portfolio of early projects in indications with high unmet medical needs, starting with Gout flare, Osteoarthritis and Hemoglobinopathies.
PK MED | Treatment in gout flares
PK MED has developed a portfolio of early projects in indications with high unmet medical needs, starting with Gout flare (PKM-01), Osteoarthritis (PKM-011) and Hemoglobinopathies (PKM-02).
https://www.pk-med.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Auvergne-Rhône-Alpes Entreprises National and local authorities, Business Consulting and Services | Auvergne-Rhône-Alpes Entreprises National and local authorities, Business Consulting and Services | Other 10 Aug 2024 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 31 Jan 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 31 Jan 2024 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 28 Jul 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 23 Jul 2024 | | |